» Articles » PMID: 39775310

Expression Analysis of Thirteen Genes in Response to Nifurtimox and Benznidazole in Mexican Isolates of Trypanosoma Cruzi by Digital PCR

Overview
Journal Acta Parasitol
Specialty Parasitology
Date 2025 Jan 8
PMID 39775310
Authors
Affiliations
Soon will be listed here.
Abstract

Despite being the most relevant and critical option for managing Chagas disease, pharmacological therapy is currently limited by the availability of only two drugs, benznidazole and nifurtimox. Their effectiveness is further restricted in the chronic phase of the infection, as they induce severe side effects and require prolonged treatment. Additionally, the use of these drugs can lead to the emergence of substantial resistance problems, compounded by the potential natural resistance of some parasite isolates. This study analyzes the expression of 13 genes by digital PCR in four Mexican T. cruzi isolates treated with NFX and BZN. Each isolate exhibited a unique combination of enzyme expression in response to the oxidative stress induced by the antichagasic agents. Notably, we observed the overexpression of cruzipain (CZP), L-threonine dehydrogenase (TDH), and detoxification-related enzymes such as Glutathionyl spermidine synthetase (GST) and Superoxide dismutase-A (SOD). These findings highlight the need for further studies to elucidate the molecular mechanisms underlying this resistance, which pose both unexpected challenges for Chagas disease therapy and a biological barrier to the action of these drugs. These findings highlight the need for further studies to understand how these resistance mechanisms contribute to treatment failure and constitute a biological barrier to drug action.

References
1.
Arnal A, Waleckx E, Rico-Chavez O, Herrera C, Dumonteil E . Estimating the current burden of Chagas disease in Mexico: A systematic review and meta-analysis of epidemiological surveys from 2006 to 2017. PLoS Negl Trop Dis. 2019; 13(4):e0006859. PMC: 6474657. DOI: 10.1371/journal.pntd.0006859. View

2.
Zingales B, Andrade S, Briones M, Campbell D, Chiari E, Fernandes O . A new consensus for Trypanosoma cruzi intraspecific nomenclature: second revision meeting recommends TcI to TcVI. Mem Inst Oswaldo Cruz. 2009; 104(7):1051-4. DOI: 10.1590/s0074-02762009000700021. View

3.
Lima L, Espinosa-Alvarez O, Ortiz P, Trejo-Varon J, Carranza J, Miguel Pinto C . Genetic diversity of Trypanosoma cruzi in bats, and multilocus phylogenetic and phylogeographical analyses supporting Tcbat as an independent DTU (discrete typing unit). Acta Trop. 2015; 151:166-77. DOI: 10.1016/j.actatropica.2015.07.015. View

4.
Revollo S, Oury B, Vela A, Tibayrenc M, Sereno D . In Vitro Benznidazole and Nifurtimox Susceptibility Profile of Trypanosoma cruzi Strains Belonging to Discrete Typing Units TcI, TcII, and TcV. Pathogens. 2019; 8(4). PMC: 6963282. DOI: 10.3390/pathogens8040197. View

5.
Vela A, Coral-Almeida M, Sereno D, Costales J, Barnabe C, Breniere S . In vitro susceptibility of Trypanosoma cruzi discrete typing units (DTUs) to benznidazole: A systematic review and meta-analysis. PLoS Negl Trop Dis. 2021; 15(3):e0009269. PMC: 8016252. DOI: 10.1371/journal.pntd.0009269. View